ISPOR 2025
Meet Fortrea’s Patient-Centered Endpoints (PaCE) Consulting team at ISPOR 2025
Meet us in Montreal, QC, Canada from May 13-16 as we take part in the leading North American conference for health economics and outcomes research (HEOR). While at ISPOR 2025, we invite you to meet with our team of Patient-Centered Endpoints (PaCE) Consulting professionals who will be on hand to discuss the key challenges you are facing in developing patient-centered measurement and evidence generation strategies to support regulatory approval and payer interactions.
Stop by any one of the eight posters Fortrea is presenting and connect with our subject matter experts presenting them.
Featured presentations
14 May 2024 | 10:30 AM - 1:30 PM | Poster Session 1
Poster Code: PCR8 | Discussion Period: 12:30 - 1:30 PM
Application of sentiment analysis to aid in evaluation of Patient Reported Outcome Measures: Analysis of qualitative cognitive debriefing interviews
Christine Bradshaw, MA; Kristina Davis, PhD; Elizabeth Merikle, PhD;
Fortrea, Durham, NC, USA
14 May 2024 | 10:30 AM - 1:30 PM | Poster Session 1
Poster Code: PCR44 | Discussion Period: 12:30 - 1:30 PM
Characterizing the experience of excessive daytime sleepiness in patients with idiopathic hypersomnia: Implications for measuring daytime sleepiness with the Epworth Sleepiness Scale in a clinical trial (NCT05156047)
Bolding S1, Merikle E1, Insana, S2, Johnston, K1, Manuel M2, WilmsenK2, Nomikos G2
1Fortrea, Inc, Durham NC, USA, 2Harmony Biosciences Management Inc., Plymouth Meeting, PA, USA
14 May 2024 | 4:00 - 7:00 PM | Poster Session 2
Poster Code: PCR95 | Discussion Period: 6:00 - 7:00 PM
State of inclusion of patient-centered endpoints in Duchenne Muscular Dystrophy (DMD) clinical trials
Bolding, S., Presnall, C., Merikle E
Fortrea, Durham, NC
14 May 2024 | 4:00 - 7:00 PM | Poster Session 2
Poster Code: PCR78 | Discussion Period: 6:00 - 7:00 PM
Approaches to Decreasing Emotional Burden during Qualitative Interviews to Improve Data Quality and Participant Engagement
Efferson, L.; Bradshaw, C.; Presnall, C., Merikle E
Fortrea, Durham, NC
14 May 2024 | 4:00 - 7:00 PM | Poster Session 2
Poster Code: PCR77 | Discussion Period: 6:00 - 7:00 PM
Development of a conceptual model of the patient experience with idiopathic hypersomnia: Patient interviews from a clinical trial (NCT05156047)
Johnston, K1, Insana, S2, Merikle E1, Manuel M2, Wilmsen K2, Presnall C1, Carlson C1, Nomikos G2
1Fortrea, Inc, Durham NC, USA, 2Harmony Biosciences Management Inc., Plymouth Meeting, PA, USA
15 May 2024 | 10:30 - 1:30 PM | Poster Session 3
Poster Code: PCR115 | Discussion Period: 12:30 - 1:30 PM
Qualitative assessment of the Idiopathic Hypersomnia Severity Scale: Suitability for use as a clinical trial endpoint as demonstrated in NCT05156047
Merikle E1, Insana, S2, Johnston, K1, Manuel M2, Wilmsen K2, Nomikos, G2
1Fortrea, Inc, Durham NC, USA, 2Harmony Biosciences Management Inc., Plymouth Meeting, PA, USA
15 May 2024 | 10:30 - 1:30 PM | Poster Session 3
Poster Code: PCR127 | Discussion Period: 12:30 - 1:30 PM
A targeted literature review of patient perspectives of placebo use in clinical trials: How can the patient voice help drug developers in trial design, recruitment, and retention?
Johnston K, Bolding S, Carlson C, Wentworth K, Merikle E
Fortrea, Inc, Durham NC, USA,
15 May 2024 | 10:30 - 1:30 PM | Poster Session 3
Poster Code: PCR109 | Discussion Period: 12:30 - 1:30 PM
Is it time to rethink proxy-reporting? Feasibility and psychometric considerations for creating ObsROs that adhere to Patient-Focused Drug Development (PFDD) fit-for-purpose guidance?
Chelsea Carlson, Kristina Davis, Elizabeth Merikle
Fortrea, Inc, Durham NC, USA,